Drugs / DT388IL3
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT00397579 | May 2013 → Jul 2017 | CD4+/CD56+ hematodermic neoplasm, leukemia, myelodysplastic syndrome | University of Texas Southwestern Medical Center | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DT388IL3 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00397579 ↗ |
| Known as | SL-401 | “Because BPDCN blasts overexpress the interleukin-3 receptor (IL3R), the activity of SL-401, diptheria toxin (DT)388IL3 composed of the catalytic and translocation domains of DT...” PMID 24859366 ↗ May 2014 |
| Modality | Protein / enzyme biologic | “DT388IL3 fusion protein” NCT00397579 ↗ |
| Route | Intravenous | “Intravenously via a 3 cc plastic syringe as a 15 minute bolus infusion daily for five days” NCT00397579 ↗ |